Dr. Hirano is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
259 East Erie (Lavin Building)
Suite 1600
Chicago, IL 60611Phone+1 312-695-5620Fax+1 312-695-3999- Is this information wrong?
Summary
- Dr. Ikuo Hirano is a gastroenterologist in Chicago, IL and is affiliated with Northwestern Memorial Hospital. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 27 years. He specializes in esophagus disease and is experienced in general gastroenterology, colonoscopy, biliary tract disease, esophageal disease, and pancreatic disease. He has more than 100 publications and over 500 citings.
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Gastroenterology, 1992 - 1995
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1992
- Perelman School of Medicine at the University of PennsylvaniaClass of 1990
Certifications & Licensure
- IL State Medical License 1998 - 2026
- MA State Medical License 1992 - 2004
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Feinberg Academy of Medical Educators (FAME) Outstanding Teacher Award Northwestern University Feinberg School of Medicine, 2015
- Gastroenterology and Hepatology Fellowship Teaching Award Northwestern University Feinberg School of Medicine, 2015
- David Graham Lecture American College of Gastroenterology, 2015
- Join now to see all
Clinical Trials
- Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index Start of enrollment: 2011 Jan 01
- Registry for Eosinophilic Gastrointestinal Disorders (REGID) Start of enrollment: 2012 Nov 01
- Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Start of enrollment: 2011 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- A Multicenter Long-Term Cohort Study of Eosinophilic Esophagitis Variants and Their Progression to Eosinophilic Esophagitis Over Time.Thomas Greuter, Alex Straumann, Yuniel Fernandez-Marrero, Nina Germic, Aref Hosseini, Apinya Chanwangpong, Shida Yousefi, Dagmar Simon, Margaret H Collins, Christian B...> ;Clinical and Translational Gastroenterology. 2024 Apr 1
- Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review.Jonathan I Silverberg, Mark Boguniewicz, Francisco J Quintana, Rachael A Clark, Lara Gross, Ikuo Hirano, Anna M Tallman, Philip M Brown, Doral Fredericks, David S Rube...> ;The Journal of Allergy and Clinical Immunology. 2023 Dec 27
- 2 citationsDupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic ...Bredenoord, A., Lucendo, A., Schlag, C., Sun, X., Mannent, L., Maloney, J., Laws, E., Mortensen, E., Shabbir, A., Hirano, I., Glotfelty, L., Dellon, E.> ;Gut. 2024 Feb 23
- Join now to see all
Journal Articles
- Anti–Siglec-8 Antibody for Eosinophilic Gastritis and DuodenitisEvan S Dellon, Kathryn A Peterson, Gary W Falk, Nirmala Gonsalves, Michael Vaezi, Adam C Bledsoe, Alan T Chang, Ikuo Hirano, The New England Journal of Medicine
- RPC4046 in Patients with Eosinophilic EsophagitisEvan S Dellon, Ikuo Hirano, Clinical Gastroenterology and Hepatology
Authored Content
- RPC4046 in Patients with Eosinophilic EsophagitisMarch 2020
Press Mentions
- Budesonide for EoE: Why the FDA Denial Is so Hard to SwallowMarch 22nd, 2022
- Is FDA Approval in Sight for Emerging EoE Therapies?March 22nd, 2022
- New Option for Eosinophilic Esophagitis?April 21st, 2021
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
- Northwestern Memorial HospitalChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: